Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. , May 24, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products…
Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress
Data Will Also Be Presented in a Poster Session at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 3, 2023 SOUTH SAN FRANCISCO, Calif. , May 11,…
Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update
Enrollment Ongoing in Industry’s First Potentially Pivotal Phase 2 Allogeneic CAR T Trial, ALPHA2, in Relapsed/Refractory Large B Cell Lymphoma Initiated Phase 2 EXPAND Trial to Support Licensure of ALLO-647…
- 1
- 2
- 3
- 4
- …
- 9
- Go to the next page